Extracorporeal Membrane Oxygenation Machine By Type (Veno-Arterial ECMO, Veno-Venous ECMO, Others), Age Group (Neonates, Paediatrics, Adults), Application (Respiratory, Cardiac) and Region Forecast 2019-2030

Extracorporeal membrane oxygenation machine market size was valued at US$ 447.9 million in 2023 and is projected to reach US$ 661.9 million by 2030 at a CAGR of 5.7% from 2024-2030. Moreover, the U.S. extracorporeal membrane oxygenation machine market is projected to grow significantly, reaching an estimated value of US$ 246.1 Million by 2030. The ECMO machine market encompasses the production, distribution, and utilization of ECMO systems designed to provide temporary mechanical support to patients with severe cardiac and respiratory failure. ECMO machines function by oxygenating blood outside the body and removing carbon dioxide, serving as an advanced life-support technology in critical care units. These systems are utilized across various healthcare settings, including hospitals, specialized critical care centres, and emergency response scenarios, aiding patients when conventional treatments prove inadequate.

The market is witnessing significant growth, driven by rising healthcare demand and advancements in medical technology. Increasing prevalence of chronic diseases such as cardiovascular disorders, respiratory failure, and ARDS has fuelled the need for innovative critical care solutions, positioning ECMO systems as an essential component of advanced medical care. The market benefits from expanding healthcare infrastructure, growing awareness among healthcare professionals, and strategic collaborations between manufacturers and healthcare institutions. Furthermore, heightened emphasis on research and development activities has led to the introduction of portable and user-friendly ECMO systems, catering to both adult and paediatric patients. North America and Europe holding prominent shares due to well-established healthcare systems, while emerging economies in Asia-Pacific are offering lucrative growth opportunities over the forecast timeframe.

List Of Top Key Players in Extracorporeal Membrane Oxygenation Machine Industry

The global market size includes several extracorporeal membrane oxygenation machine companies such as Medtronic, Getinge AB, Terumo corporation, Liva nova plc, Fresenius Medical Care, Nipro Corp, Abbott, Micro-port Scientific Corp, Philips, Origen Biomedical, Inc.

Facts & Figures

• In fact, Veno-Arterial (VA) ECMO accounts for the largest share at 47.09%, with a CAGR of 5.87%, due to its application in critical cardiac conditions like cardiogenic shock and cardiac arrest.
• The adult age group leads the market with 60.06% market share and a CAGR of 5.97%, driven by rising cases of acute respiratory distress syndrome (ARDS) and severe cardiac failures among adults.
• Respiratory applications dominate with 50.09% of the market share and a CAGR of 5.43%, driven by the increasing prevalence of respiratory disorders such as ARDS, COPD, and severe pneumonia, particularly highlighted during the COVID-19 pandemic.
• North America holds the largest market share at 42.16%, attributed to advanced healthcare infrastructure, high healthcare spending, and a growing number of ECMO centres.

List of Instances

• In October 2024, Fresenius Medical Care’s heart & lung business unit, Xenios AG, introduced the all-new Xenios 2.0 system. This advanced system empowers healthcare professionals to take the next crucial step in extracorporeal life support (ECLS). It is designed to support a full range of ECLS treatments for patients of all ages, from neonates to adults, and is approved in accordance with the new Medical Device Regulation (MDR).
• In May 2024, The FDA issued a letter to healthcare providers and facilities highlighting "ongoing safety and quality concerns" regarding Getinge/Maquet cardiovascular medical devices. The warning encompasses the Getinge/Maquet/Data scope Cardiosave Hybrid and Rescue Intra-Aortic Balloon Pump (IABP) devices, as well as the Getinge/Maquet Cardio help system and HLS sets. The FDA has recommended that healthcare facilities transition away from using these devices and explore alternative solutions where feasible. These recommendations stem from the agency's persistent concerns that Getinge/Maquet has not adequately resolved the issues and risks associated with these recalled products.
• In June 2022, Terumo Corporation announces the appointment of three associates as the newest "Terumo Fellow" to recognize outstanding contributions to healthcare innovation and advancements in technology, research, clinical, and regulatory affairs within the Terumo Group. Akio Kutsuzawa, General Manager of ME R&D in the Cardiac and Vascular Company, is recognized for his significant achievements in the ECMO market, including the commercialization and mass production of the controller for the extracorporeal membrane oxygenation (ECMO) system.

Key Developments

• In September 2024, Medtronic, plc., a global leader in medical technology, introduced the Vital Flow™ ECMO System, a versatile and configurable solution designed to deliver simplicity and performance. The system aims to bridge the gap between bedside care and intra-hospital transport, providing physicians and clinicians with a more efficient and intuitive ECMO experience.
• In May 2024, Hemovent GmbH (Hemovent) announced that its innovative integrated portable pneumatic extracorporeal membrane oxygenation (ECMO) system, the MOBYBOX®, has completed its first batch of commercial deployments in Europe. The system has demonstrated its exceptional portability through multiple intra-hospital and inter-hospital transfers. To date, the MOBYBOX® is the only ECMO system to have received Medical Device Regulation Certification. The system has been launched in global markets, including Germany, The Netherlands, Italy, Greece, and Israel, with ongoing efforts to expand market access in several Middle Eastern countries, as well as in the United States and China.
• In April 2023, Abbott received two additional FDA clearances for its industry-leading life support system. The CentriMag Blood Pump, when used with the CentriMag™ System, is now approved for longer-term usage in adults requiring extracorporeal membrane oxygenation (ECMO), a life-saving treatment for patients with heart and lung failure. This extended clearance gives clinicians more time to assess next steps and make key care decisions for their patients, increasing the flexibility and effectiveness of ECMO therapy.

Extracorporeal Membrane Oxygenation Machine Market Segmentation:

By Type: Veno-Arterial (VA) ECMO leads the ECMO machine market, accounting for 47.09% of the total share, driven by its critical role in supporting patients with severe cardiac dysfunction or cardiogenic shock. VA ECMO is increasingly utilized in cases of cardiac arrest, refractory heart failure, and complications during high-risk cardiac surgeries due to its ability to provide both circulatory and respiratory support. The rising incidence of cardiovascular diseases, which remain the leading cause of mortality globally, significantly contributes to the demand for VA ECMO systems.

Advancements in VA ECMO technology, including portable systems and user-friendly interfaces, have further enhanced its adoption in emergency and critical care settings. These systems are increasingly being integrated with real-time monitoring capabilities, allowing healthcare providers to manage patients more effectively. Additionally, the growing trend of utilizing VA ECMO as a bridge-to-recovery or bridge-to-transplant therapy has expanded its applications, particularly in advanced heart failure cases. The robust growth of VA ECMO is supported by heightened awareness among clinicians, specialized training programs, and substantial investments in cardiac care infrastructure across leading healthcare markets.

By Age Group: The adult segment leads the ECMO machine market, accounting for 60.06% of the market share, with a CAGR of 5.97%. This is primarily driven by the increasing prevalence of acute and chronic conditions, such as acute respiratory distress syndrome (ARDS), severe pneumonia, and cardiovascular diseases, among the adult population. These conditions are often exacerbated by lifestyle factors like smoking, obesity, and sedentary habits, leading to a higher demand for life-support interventions such as ECMO systems. For instance, the global rise in ARDS cases during the COVID-19 pandemic highlighted the critical role of ECMO in managing severe respiratory failure in adults.

Another key driver is the growing use of ECMO as a rescue therapy in adult patients undergoing complex surgical procedures or experiencing post-operative complications. Technological advancements, such as portable ECMO machines and advanced oxygenation systems, have made it easier to deploy ECMO in various clinical settings, including emergency care and transport scenarios. The increased awareness and adoption of ECMO as a bridge-to-recovery or bridge-to-transplant therapy in adults with severe heart or lung failure further amplify its demand. Additionally, investments in critical care infrastructure and specialized training for healthcare providers contribute to the sustained growth of the adult segment in the ECMO market.

By Application: The respiratory segment leads the ECMO machine market, holding 50.09% of the market share, with a CAGR of 5.43%. This leadership is driven by the growing prevalence of respiratory disorders such as acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), and severe pneumonia. The COVID-19 pandemic further underscored the importance of ECMO as a critical intervention in managing severe respiratory failure, significantly increasing its adoption worldwide. With the rising incidence of lung-related diseases due to factors such as air pollution, smoking, and occupational hazards, the demand for ECMO systems in respiratory applications continues to grow over the forecast period.

Technological advancements have enhanced the effectiveness of ECMO in respiratory care. Innovations such as improved oxygenators, real-time blood gas monitoring, and portable ECMO devices have made the technology more accessible and safer for respiratory management. Additionally, the adoption of ECMO as a life-saving measure in extreme cases, including trauma and severe infections leading to respiratory collapse, has expanded its scope. Specialized training programs for healthcare providers and the establishment of dedicated ECMO centres have further facilitated the growth of this segment. These factors collectively position respiratory applications as the largest and one of the fastest-growing segments in the ECMO machine market.